The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

Inclusion Criteria:

* Written informed consent given;
* Have medically documented cancer for which Taxotere® monotherapy would be a suitable treatment option;
* Aged ≥18 years;
* Eastern Cooperative Oncology Group (ECOG) performance status between 0 - 1 (inclusive);
* Haematological and serum chemical parameters that comply with the following criteria (based on local laboratory normal reference range):

  * Haemoglobin ≥9.5 g/dL
  * Leukocytes ≥3.0 x 10\^9/L
  * Neutrophils ≥1.5 x 10\^9/L
  * Platelets ≥100 x 10\^9 L
  * Total bilirubin ≤2.0 x Upper Limit of Normal (ULN)
  * Aspartate aminotransferase (AST) ≤2.5 x ULN
  * Alanine aminotransferase (ALT) ≤2.5 x ULN
  * Alkaline phosphatase ≤4.0 x ULN
  * Serum creatinine ≤1.5 x ULN
* Willing to use an effective method of contraception, i.e. intrauterine device (IUD), oral contraceptive, subdermal implant or double barrier (condom with a contraceptive sponge or contraceptive suppository), unless anatomically sterile, from screening until at least 12 weeks after last dose of Investigational Medicinal Product.
* Willing and able to comply with the requirements of the protocol and available for the planned duration of the study.

Exclusion Criteria:

* Concomitant treatment with any other cytotoxic agent;
* Concomitant use of compounds that induce, inhibit or are metabolized by cytochrome P450, e.g. ciclosporin, ketoconazole, erythromycin, St John's Wort;
* History or presence of any clinically significant findings that, in the opinion of the Investigator, would preclude inclusion in the study;
* Clinically significant vital signs or 12-lead electrocardiogram (ECG) results, as judged by the Investigator;
* Participation in any other clinical trial using an Investigational Medicinal Product within the previous month
* History of Hepatitis B Virus, Hepatitis C Virus or Human Immunodeficiency Virus;
* Recent or clinically significant history of drug or alcohol abuse;
* Insulin-dependent or unstable Diabetes Mellitus;
* History of severe hypersensitivity reactions to Taxotere® or to other drugs formulated with Polysorbate 80;
* History of reaction to any drug containing polyethylene glycol 300 (PEG 300);
* Pregnancy or lactation.